Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2023-08-02 Director's Dealing
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share ownership and specific transaction changes (in this case, an acquisition) by an executive (Kim In Ok) of the company Antrogen. This type of filing is classified as a Director's Dealing (DIRS) report, as it documents insider share transactions.
2023-08-02 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(ANT-301 국내 제 1/2a상 임상시험계획 승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the company Antrogen regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an application for clinical trial approval (IND) to the Korean Ministry of Food and Drug Safety. Since this is a specific regulatory disclosure of a material event that does not fit into categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2023-07-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company 'Antrogen', detailing the date, location, and agenda items (specifically the appointment of an auditor). This type of document, which provides information to shareholders regarding an upcoming meeting and the items to be voted upon, is classified as a Proxy Solicitation & Information Statement.
2023-07-19 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (임시주주총회). It does not contain the full proxy materials or the meeting results themselves, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement and its brevity, it falls under the general regulatory filing category.
2023-07-19 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(ANT-301의 제1/2a상 임상시험계획)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Antrogen) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a clinical trial (ANT-301). Since this is a formal regulatory disclosure of a specific corporate event that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-06-15 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제5회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the Korean Exchange (KRX) regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). It details the specific bond series, the amount acquired, the reason (early redemption request by the bondholder), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding bond acquisition/redemption, it fits best under the 'Capital/Financing Update' category.
2023-06-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.